February 1, 2013

There is always a first time

It was not until yesterday that we knew that for the first time two drugs were not included in the publicly funded package because its low cost-effectiveness. This is a historical achievement. The news is so unique that deserves explanation. For decades, health economists have been asking for the economic evaluation of new benefits. Surprisingly, yesterday there was anounced in the press that two cancer drugs with limited effectiveness and high costs were not entering into public funding. My question is, how the regulator has come to such a decision if the committees set up by the law have not been nominated?. The answer is in the journal. Up to now, the institution that rules cost-effectiveness are the officials in the Ministry, that's all. NTA: Nothing to add.